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DObjectives: Experience with extracorporeal membrane oxygenation for adult patients with refractory septic
shock remains limited. We aimed to study the clinical features and outcomes of this patient group in an extra-
corporeal membrane oxygenation referral center in Taiwan.
Methods: From January 2005 to December 2010, all adult patients in refractory septic shock and requiring
venoarterial extracorporeal membrane oxygenation for circulatory support were included in the present study.
The variables analyzed included patient demographics; comorbidities; smoking status; hemodynamic, ventila-
tory, and laboratory parameters just before extracorporeal membrane oxygenation support; clinical course;
extracorporeal membrane oxygenation details; complications; microbiology results; and outcomes. The primary
endpoint was survival to hospital discharge.
Results: A total of 52 patients, 39 men and 13 women, were included during a 6-year period. Their median age
and body mass index was 56.8 years and 24.1 kg/m2, respectively. Of the 52 patients, 39 (75%) had failure of at
least 3 organ systems and 21 (40%) had developed cardiac arrest and received cardiopulmonary resuscitation at
extracorporeal membrane oxygenation implantation. Of these 52 patients, 8 (15%) survived to hospital dis-
charge. The nonsurvivors were significantly older than the survivors (59.3 vs 43.8 years; P ¼ .009), and all
20 patients (38%) aged 60 years or older died.
Conclusions: In our single-center experience with extracorporeal membrane oxygenation for adults with refrac-
tory septic shock, the outcomes of these patients remain unsatisfactory. From our findings, we suggest that if
extracorporeal membrane oxygenation were to be used in this patient population, age 60 years or older might
be a contraindication. Also, central extracorporeal membrane oxygenation could possibly be beneficial accord-
ing to the favorable pediatric experience in published studies. (J Thorac Cardiovasc Surg 2013;146:1041-6)Septic shock, the most severe form of sepsis, is a common
disease process in critically ill patients.1 Despite advances
in critical care and the availability of potent antimicrobial
therapy, the mortality rate associated with septic shock
remains high, largely owing to the progressively compro-
mised organ perfusion and development of multiple organ
failure.2,3 For septic shock unresponsive to all other
measures, the American College of Critical Care Medicine
has suggested that extracorporeal membrane oxygenation
(ECMO) is a viable therapy in neonates and children.4
However, although successful use of ECMO in adults with
refractory septic shock has been reported in a few cases,5-8
the experience with ECMO in adults with septic shock
remains limited.
Accordingly, we performed a retrospective cohort study
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The Journal of Thoracic and Carseptic shock and aimed to describe the clinical features
and survival of this patient group.METHODS
Study Population
The present study was conducted at the National Taiwan University
Hospital, a university-affiliated hospital with a 2200-bed capacity in North-
ern Taiwan. It delivers both primary and tertiary healthcare and also has an
ECMO referral center. For quality assurance, a computerized case record
form was established to prospectively collect the demographic, clinical
features, and outcomes of patients undergoing ECMO.9 We searched the
ECMO database for adult patients who required ECMO for refractory sep-
tic shock between January 2005 and December 2010. Patients were eligible
for the present study if they were 18 years or older, had received venoarte-
rial ECMO for circulatory collapse despite fluid resuscitation and inotropic
therapy, had a clinical diagnosis of septic shock, and had a positive culture
or serology result for potentially pathogenic microorganisms before
ECMO implantation. Patients were excluded if they had received ECMO
primarily for respiratory support. The institutional review board approved
the present study and waived the need for informed consent.
General Management of Septic Shock
A severe sepsis management protocol has been implemented according
to the Surviving Sepsis Campaign guidelines at our institution since
2005.10 In brief, patients presenting to the intensive care unit with septic
shock are initially treated with aggressive fluid challenge. If fluid-
refractory shock persists, a vasoactive agent, such as dopamine or norepi-
nephrine, is administered. Measurements of central venous pressure, cen-
tral venous oxygen saturation, and serum lactate are performed early todiovascular Surgery c Volume 146, Number 5 1041
Abbreviation and Acronym
ECMO ¼ extracorporeal membrane oxygenation
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Dguide fluid and inotropic therapy. Arginine vasopressin or epinephrine is
given if a patient shows signs of ongoing shock or progressive organ dys-
function. Low-dose corticosteroid infusion and packed red blood cell trans-
fusion are considered in the case of refractory shock.
ECMO Setup
Cannulation was performed by cardiovascular surgeons, who generally
cannulated the femoral artery and vein. Only if it was difficult to obtain pe-
ripheral vascular access or left-sided decompression was required was cen-
tral cannulation through a median sternotomy performed. The ECMO
system consisted of a centrifugal blood pump (Bio-Pump BP-80;
Medtronic, Minneapolis, Minn), a hollow-fiber membrane oxygenator
(Affinity; Omnis AOTGmbH, Bad Oyenhausen, Germany) with an integral
heat exchanger, and 2 thin-walled cannulae (Medtronic Inc, Anaheim,
Calif), all of which were coated with a heparin-bonded Carmeda BioActive
Surface (Carmeda AB, Upplands V€asby, Sweden). A distal reperfusion
catheter was inserted to prevent distal limb ischemia, as clinically indi-
cated.11 Anticoagulation was achieved with intravenous unfractionated
heparin infusion to maintain the activated clotting time at 180 to 220 sec-
onds. The blood flow was usually started at a rate of 2 to 2.5 L/min and then
adjusted according to the patient’s hemodynamic status.
Data Collection
The variables retrieved included patient demographics; comorbidities;
smoking status; hemodynamic, ventilatory, and laboratory data just before
ECMO support; clinical course; ECMO details; complications; microbiol-
ogy results; and outcomes. The primary endpoint was survival to hospital
discharge. Organ failure was defined using the International Sepsis Defini-
tions Conference criteria.12 A major bleeding complication during ECMO
support was defined as the transfusion of 2 U or more of packed red blood
cells, a decrease in hematocrit of 10% or more, or any bleeding requiring
surgical intervention or directly resulting in death. Appropriate antibiotic
therapy was defined as effectiveness against the culprit microorganisms
of at least 1 of the empirically selected antibiotics on the day of the
ECMO implantation. Antibiotic effectiveness was evaluated according to
the culture results and known susceptibility of the microorganism to the an-
tibiotics prescribed and by antimicrobial susceptibility testing.
Statistical Analysis
Data are presented as numbers and percentages or median and interquar-
tile range. Continuous variables were analyzed using the Mann-Whitney
U-test and categorical variables using the Fisher exact test. Survival curves
were plotted using the Kaplan-Meier method and compared using the log-
rank test. All statistics were 2-tailed. Statistical analyses were performed
using the SPSS statistical software, version 15.0 (SPSS Inc, Chicago, Ill).RESULTS
A total of 52 patients (7.9%), 39men and 13women,were
recruited from a total of 659 ECMO runs during the 6-year
study period. The median age and body mass index was
56.8 years (interquartile range, 42.7-63.6) and 24.1 kg/m2
(interquartile range, 21.2-27.5), respectively (Table 1).
Diabetes mellitus (12/52; 23%), coronary artery disease
(6/52; 12%), and end-stage renal disease (6/52; 12%)
were the most common comorbid diseases. The median1042 The Journal of Thoracic and Cardiovascular Sursequential organ failure assessment scorewas 16 (interquar-
tile range, 13-18), and 39 patients (75%) had failure of at
least 3 organ systems. The patients receivedECMOfor ame-
dian duration of 15.0 hours (interquartile range, 6.1-29.3) af-
ter the onset of septic shock. All patients had been
orotracheally intubated and administered on mechanical
ventilation before ECMO support. The survivors (age,
43.8 years) were significantly younger than the nonsurvivors
(age, 59.3 years), and all 20 patients (38%) aged 60 years or
older died.
The most common infection sites were the lung and
abdomen, accounting for 69% of the infections, and 23
patients (44%) had positive blood cultures (Table 2). The
infections were bacterial in most (88%) patients, and
gram-negative bacteria were isolated from 60% of the
patients. Klebsiella pneumoniae and Pseudomonas aerugi-
nosa were the most frequently identified pathogens. Of the
52 patients, 43 (83%) had received appropriate antimicro-
bial agents on the day ECMO was instituted.
The circulatory, ventilatory, and laboratory variables
before ECMO support are listed in Table 3. None of 52 pa-
tients had a history of congestive heart failure or developed
acute heart failure or coronary events; however, 11 patients
(21%; 1 survivor and 10 nonsurvivors) had a decreased left
ventricular ejection fraction of less than 50%, as evaluated
by echocardiography at ECMO implantation. The survivors
tended to have a lower pre-ECMO arterial lactate level than
the nonsurvivors.
Of the 52 patients, 21 (40%) developed rapid and severe
hemodynamic deterioration and cardiac arrest and received
cardiopulmonary resuscitation before the decision to insti-
tute ECMO support. The median duration of cardiopulmo-
nary resuscitation was 29.0 minutes (interquartile range,
23.0-35.5; Table 4). A total of 36 patients (69%) required
hemofiltration during ECMO. The median duration of
ECMO was 43.3 hours (interquartile range, 10.2-157.5).
The survivors (162.9 hours) received ECMO for a signifi-
cantly longer period than the nonsurvivors (27.3 hours).
With respect to ECMO cannulation, the cannulae were
placed in the femoral vein and artery (femoral–femoral can-
nulation) in all but 2 patients; 1 received jugular–femoral
cannulation and 1 femoral–carotid cannulation. No patients
required left-sided decompression or underwent central
cannulation.
Of the 52 patients, 12 (23%) experienced mechanical
problems during ECMO support, including 9 oxygenator
failures, 4 occasions in which a cannula needed to be repo-
sitioned, and 1 episode of blood clots in the circuit. Of these
12 patients, 2 experienced 2 different mechanical problems.
There were 4 (7.7%) major bleeding complications; 2 pa-
tients developed bleeding from the cannulation sites and 2
developed gastrointestinal hemorrhage, all of whom were
treated conservatively. No patients died of these complica-
tions. All patients underwent instrumentation with a rightgery c November 2013
TABLE 1. Baseline patient characteristics
Characteristic
Survivors
(n ¼ 8)
Nonsurvivors
(n ¼ 44) P value
Age (y) 43.8 59.3 .009
Age 60 y 0 (0) 20 (45) .017
Male gender 7 (88) 32 (73) .662
BMI (kg/m2) 25.7 24.1 .417
Current smoker 0 (0) 12 (27) .174
Comorbidities 1 (13) 20 (46) .122
Diabetes mellitus 0 (0) 12 (27) .174
Coronary artery disease 0 (0) 6 (14) .573
End-stage renal disease 1 (13) 5 (11) .999
Chronic obstructive
pulmonary disease
0 (0) 2 (5) .999
Liver cirrhosis 0 (0) 1 (2) .999
SOFA score 15 17 .546
Dysfunctional organs 3.5 3.0 .844
Patients with 3 dysfunction
organs
6 (75) 33 (75) .999
Interval from shock to start
of ECMO (h)
20.8 15.0 .630
Data presented as n (%) or median. BMI, Body mass index; SOFA, sequential organ
failure assessment; ECMO, extracorporeal membrane oxygenation.
TABLE 2. Sites and causes of infections in patients with refractory
septic shock
Variable
Survivors
(n ¼ 8)
Nonsurvivors
(n ¼ 44) P value
Infection sites .391
Lung 6 (75) 19 (43)
Abdomen 1 (13) 10 (23)
Urinary tract 0 (0) 5 (11)
Others* 1 (13) 10 (23)
Positive blood culture 4 (50) 19 (43) .999
Microorganism types .277
Gram-positive 3 (38) 11 (25)
Staphylococcus species 3 (38) 4 (9)
Streptococcus species 0 (0) 4 (9)
Enterococcus species 0 (0) 2 (5)
Other gram-positive bacteria 0 (0) 1 (2)
Gram-negative 3 (38) 28 (64)
Klebsiella pneumoniae 0 (0) 8 (18)
Pseudomonas aeruginosa 0 (0) 8 (18)
Enterobacter species 1 (13) 3 (7)
Acinetobacter baumannii 1 (13) 2 (5)
Escherichia coli 0 (0) 2 (5)
Citrobacter species 1 (13) 1 (2)
Other gram-negative bacteria 0 (0) 4 (9)
Fungal
Candida species 2 (25) 3 (7)
Other
Mycoplasma pneumoniae 0 (0) 1 (2)
Influenza type A 0 (0) 1 (2)
Appropriate antibiotic therapy 6 (75) 37 (84) .615
Data presented as n (%). *Other sites of infections included blood, skin and soft
tissue, bones, and cardiac system.
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ygen was clinically observed.
The median duration of the intensive care unit and hospi-
tal stay was 90.1 hours (interquartile range, 28.3-314.7) and
114.1 hours (interquartile range, 52.3-404.7), respectively.
Of the 52 patients, 8 (15%) survived to hospital discharge.
Of those who died, 28 (64%) died of refractory circulatory
collapse within 48 hours after initiation of ECMO
(Figure 1). The survival analysis showed that patients youn-
ger than 60 years had significantly better survival than those
60 years old or older (log-rank, P¼ .029). Three of the non-
survivors survived to be taken off ECMO; however, later, 2
died of hospital-acquired pneumonia and 1 died of a perfo-
rated peptic ulcer in the intensive care unit.
DISCUSSION
The present study was dedicated to investigate how well
ECMO performs as rescue therapy for refractory septic
shock in adults. The main findings were that the survival
of patients with refractory septic shock and receiving
ECMO support remains unsatisfactory and that age was
the only independent factor associated with mortality in
our study population.
Sepsis was once regarded as a contraindication for
ECMO because the artificial circuits could harbor microor-
ganisms and cause severe uncontrolled infection. However,
advances in ECMO management and circuit technology
have broadened the indications for ECMO, and patients
with sepsis are no longer excluded as candidates for
ECMO. Most promisingly, a survival rate of up to 74%
was observed in children receiving ECMO as circulatoryThe Journal of Thoracic and Carsupport for refractory septic shock.13,14 In the present
study, we reported a large case series of the application of
ECMO in adult patients with refractory septic shock and
found a prognosis for adults distinct from that for
children. Several factors could account for the favorable
outcome for pediatric patients. First, septic shock has
a variety of hemodynamic presentations. Left ventricular
dysfunction with reduced cardiac output is commonly
seen in infants and younger children; however,
distributive shock, a hyperdynamic state with high cardiac
output, usually manifests in older children and adults.15
Venoarterial ECMO is used primarily for cardiac or cardio-
pulmonary support and is intuitively more beneficial for
patients with ventricular dysfunction than for those with
profound vasodilation. Thus, the performance of ECMO
is probably better in pediatric than adult septic shock.
Second, a significant proportion of pediatric patients with
refractory septic shock underwent ECMO by central cannu-
lation.13,14 In contrast, all of our patients with refractory
septic shock received peripheral ECMO cannulation.
Central cannulation might be associated with increased
survival in the pediatric population. Its theoretical benefits
include the ability to achieve greater flow rates anddiovascular Surgery c Volume 146, Number 5 1043
TABLE 3. Clinical parameters before extracorporeal membrane
oxygenation
Variable
Survivors
(n ¼ 8)
Nonsurvivors
(n ¼ 44)
P
value
Circulatory
Mean arterial pressure (mm Hg) 57.0 55.5 .424
Inotropic equivalent* (mcg/kg/min) 52.8 56.0 .275
Urine output in hour before
ECMO (mL/kg/h)
0.07 0.02 .493
Left ventricular ejection
fraction (%)
56.5 55.5 .657
Ventilatory
Peak airway pressure (cm H2O) 30 30 .980
Mean airway pressure (cm H2O) 17 15 .341
Positive end-expiratory
pressure (cm H2O)
11 8 .150
FIO2 0.65 0.60 .552
Laboratory
pH 7.32 7.30 .960
PaO2/FIO2 89 112 .233
PaCO2 (mm Hg) 37.6 38.1 .704
Base excess (mmol/L) 6.6 6.3 .899
Arterial lactate (mmol/L) 5.3 8.8 .089
Data presented as median. ECMO, Extracorporeal membrane oxygenation;FIO2, frac-
tion of inspired oxygen; PaO2, arterial oxygen tension; PaCO2, alveolar carbon dioxide
tension. *Inotropic equivalent ¼ dopamine þ dobutamine þ 100 3 epinephrine þ
100 3 norepinephrineþ100 3 isoproterenolþ15 3 milrinone.
FIGURE 1. Survival curves for adult patients receiving extracorporeal
membrane oxygenation for refractory septic shock. A significant propor-
tion of patients died of refractory circulatory collapse within 2 days of ini-
tiation of extracorporeal membrane oxygenation support. Survival curves
were plotted using the Kaplan-Meier method and compared using the
log-rank test.
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placement of the arterial cannula in the ascending aorta,
which possibly improves cerebral perfusion and decreases
the risk of neurologic injury compared with peripheral
cannulation.13,14 Although the present study did not
demonstrate a favorable outcome in adult patients
undergoing ECMO for refractory septic shock, our
findings have several implications. First, at present,
ECMO is not recommended for use in routine clinical
practice to rescue adult patients with refractory septic
shock. Second, if it is used to treat such patients, the useTABLE 4. Variables during ECMO in patients with refractory septic
shock
Variable
Survivors
(n ¼ 8)
Nonsurvivors
(n ¼ 44) P value
E-CPR 2 (25) 19 (43) .449
CPR duration (min) 30 29 .952
Maximal recorded flow (L/min) 2.6 2.7 .929
Hemofiltration 5 (63) 31 (71) .689
Complications 4 (50) 10 (23) .189
Mechanical* 3 (38) 9 (20) .366
Hemorrhagey 2 (25) 2 (5) .107
ECMO duration (h) 162.9 27.3 .007
Data presented as n (%) or median. ECMO, Extracorporeal membrane oxygenation;
E-CPR, ECMO with continuous cardiopulmonary resuscitation; CPR, cardiopulmo-
nary resuscitation. *Mechanical complications included oxygenator failure, cannula
repositioning, and clot in circuit. yHemorrhage complications included gastrointesti-
nal hemorrhage and cannulation site bleeding.
1044 The Journal of Thoracic and Cardiovascular Surof central ECMO or other modifications should be
seriously considered. Third, patient selection could be of
paramount importance. For example, it is probably more
appropriate to provide ECMO for patients with sepsis-
associated myocardial dysfunction.
Most of our patients had preserved left ventricular sys-
tolic function at ECMO implantation and were intuitively
considered to have distributive shock. This patient popula-
tion might not traditionally be candidates for ECMO sup-
port. However, in the case of profound septic shock, it is
difficult to determine whether the so-called preserved sys-
tolic function is sufficient to sustain the increased circula-
tory load that occurs in patients with thyrotoxicosis and
high-output heart failure.16 Therefore, under such circum-
stances, we considered that it might still be beneficial to
augment cardiac output using venoarterial ECMO to over-
come the circulatory disaster.
One of the most important considerations for the institu-
tion of ECMO for refractory septic shock is whether the in-
fection of a patient with refractory septic shock is under
control. However, most of our patients experienced refrac-
tory septic shock or even cardiac arrest shortly after the on-
set of septic shock. At that time, it was difficult for
clinicians to determine whether the infection could be suc-
cessfully treated. Thus, other clinical characteristics should
be sought to guide the application of ECMO in this regard.
The present study found age was the only recognized prog-
nostic variable in adults with refractory septic shock, and no
patient aged 60 years or older survived to hospital dis-
charge. This is in line with previous case reports5-8 that
demonstrated successful rescue of refractory septic shock
by ECMO in patients aged 18 to 46 years. Age is angery c November 2013
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various diseases.17-19 Many physiologic and immunologic
functions in the human body are dynamically changing
during the aging process, and these might not be easily
measured in the clinical context. Accordingly, from our
experience, we suggest that ECMO resuscitation might be
contraindicated for patients aged 60 years or older who
develop refractory septic shock.
The distribution of causative microorganisms and infec-
tion sites in our study was consistent with previous re-
ports.20-22 Aerobic gram-negative bacteria were more
common than aerobic gram-positive bacteria, and the lung,
abdomen, and urinary tract accounted for most cases. In
keeping with the published data,20 neither the infection site
nor the causativemicroorganismwas associatedwithmortal-
ity in the patientswith septic shock requiringECMOsupport.
Several studies and meta-analyses have shown the favorable
effect of early appropriate antimicrobial therapy in patients
with severe sepsis and septic shock.20,23,24 However,
appropriate antibiotic therapy did not appear to confer
a survival advantage in our patients. We speculate that an
overwhelmingly uncontrolled inflammatory response plays
a dominant role in these extremely critically ill patients,
overriding the benefits of appropriate antibiotic therapy
and leading to multiple organ dysfunction and, eventually,
death.25
One might be wondering whether the patients in our
study could have survived refractory septic shock without
the use of ECMO. We believe this would not have been
the case because, despite rescue by ECMO, the outcomes
of the patients remained ominous. Moreover, all patients
had profound shock and multiple organ dysfunction while
receiving high-dose inotropic therapy. Two fifths of the pa-
tients had experienced cardiac arrest before receiving
ECMO and this might partly explain the observed poor
prognosis for our septic patients. Although it would be
best to conduct a randomized trial to provide convincing ev-
idence to answer the question, such a trial of a life-support
technique in an acute fatal illness presents ethical problems,
especially when the endpoint is death. Thus, our study has
presented a large case series and might provide the strongest
evidence to date in this regard.
The present study had some limitations that need to be
addressed. This study presented a single-institution experi-
encewith the application of ECMO in adult patients with re-
fractory septic shock. Undoubtedly, the study setting
limited the strength and generalizability of the results. Nev-
ertheless, our report provides the largest case series detail-
ing the use of ECMO in such circumstances. With more
widespread application of ECMO in the near future, it
would be wise to perform a multicenter study of the popu-
lation of interest to improve our understanding. Further-
more, the possibility of selection bias and low statistical
power owing to the relatively small number of casesThe Journal of Thoracic and Carincluded in the analysis could not be excluded, and we
might have failed to identify possible associated risk factors
for mortality.
CONCLUSIONS
The outcome for ECMO resuscitation of adult patients
with septic shock unresponsive to aggressive medical ther-
apy remains poor. At present, it should not be regarded as
a rescue modality for these patients. Furthermore, if
ECMO is to be used for adult patients with refractory septic
shock, some points merit consideration. First, patient age of
60 years or older might be a contraindication. Second, these
patients might require central ECMO rather than peripheral
venoarterial ECMO according to the published pediatric ex-
perience. Finally, the characteristics, clinical course, and
outcomes of these patients should be systematically moni-
tored to help us understand this issue more deeply.
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